Eagle's Eye View: Your Weekly CV Update From ACC.org Left Atrial Appendage Occlusion & Stroke, Hypertrophic Cardiomyopathy in Children, Anticoagulation & COVID-19
7 snips
Jan 22, 2025 Discover the latest innovations in cardiovascular care, including advanced strategies for preventing strokes in patients with atrial fibrillation. Dive into promising treatments for hypertrophic cardiomyopathy in children, highlighting significant medical advancements. Plus, explore tailored anticoagulation strategies for patients affected by COVID-19, revealing insights into managing risks and improving outcomes in this challenging context.
AI Snips
Chapters
Transcript
LAAO for Stroke Prevention
- Left atrial appendage occlusion (LAAO) is increasingly used for stroke prevention in atrial fibrillation (AFib).
- LAAO may become a preferred alternative to anticoagulants, offering patients a choice.
New Drug for Severe HCM in Children
- Tremetamib shows promise in treating severe hypertrophic cardiomyopathy (HCM) in children with specific genetic variants.
- Early trials indicate reduced need for death, transplant, or cardiac surgery, though dermatologic side effects are common.
Anticoagulation in Hospitalized COVID-19 Patients
- Therapeutic dose anticoagulation may be preferable to prophylactic doses in hospitalized COVID-19 patients.
- A study suggests therapeutic doses can reduce mortality from roughly 10% to 8%.